Hutchison China Meditech Limited Blocklisting Six Monthly Return (9071S)

TIDMHCM

RNS Number : 9071S

Hutchison China Meditech Limited

29 June 2018

Blocklisting Six Monthly Return

London: Friday, June 29, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.   Name of applicant:       Hutchison China MediTech Limited 
2.   Name of scheme:          (a)    Share Option Scheme conditionally 
                                      adopted by Hutchison China 
                                      MediTech Limited in 2005 ("2005 
                                      HCML Share Option Scheme") 
                              (b)    Share Option Scheme conditionally 
                                      adopted by Hutchison China 
                                      MediTech Limited in 2015 ("2015 
                                      HCML Share Option Scheme") 
3.   Period of return:        From December 29, 2017 to June 
                               28, 2018 
4.   Balance under            (a)          2005 HCML Share Option Scheme: 
      scheme from previous                  304,999 ordinary shares of 
      return:                               US$1 each 
                              (b)          2015 HCML Share Option Scheme: 
                                            1,000,000 ordinary shares of 
                                            US$1 each 
5.   The amount by            (a)    2005 HCML Share Option Scheme: 
      which the block                 Nil 
      scheme has been 
      increased, if 
      the scheme has 
      been increased 
      since the date 
      of the last return: 
                              (b)    2015 HCML Share Option Scheme: 
                                      1,425,597 ordinary shares of 
                                      US$1 each 
6.   Number of securities     (a)    2005 HCML Share Option Scheme: 
      issued/allotted                 85,646 ordinary shares of US$1 
      under scheme during             each 
      period: 
                              (b)    2015 HCML Share Option Scheme: 
                                      Nil ordinary shares of US$1 
                                      each 
7.   Balance under            (a)    2005 HCML Share Option Scheme: 
      scheme not yet                  219,353 ordinary shares of 
      issued/allotted                 US$1 each 
      at end of the 
      period: 
                              (b)    2015 HCML Share Option Scheme: 
                                      2,425,597 ordinary shares of 
                                      US$1 each 
8.   Number and class         (i)    2,560,606 ordinary shares of 
      of securities                   US$1 each admitted on June 
      originally listed               26, 2007 
      and the date of 
      admission: 
                              (ii)   1,000,000 ordinary shares of 
                                      US$1 each admitted on June 
                                      20, 2016 
                              (iii)  1,425,597 ordinary shares of 
                                      US$1 each admitted on April 
                                      27, 2018 
9.   Total number of          66,532,683 ordinary shares of 
      securities in            US$1 each 
      issue at the end 
      of the period: 
Name of contact:              Christian Hogg 
Address of contact:           21/F., Hutchison House, 10 Harcourt 
                               Road, Hong Kong 
Telephone number 
 of contact:                  +852 2121 8200

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, 
 Corporate Finance & Development       +852 2121 8200 
 
U.K. & International Media Enquiries 
Anthony Carlisle,                      +44 7973 611 888 (Mobile) 
 Citigate Dewe Rogerson                 anthony.carlisle@cdrconsultancy.co.uk 
 
U.S. Based Media Enquiries 
Brad Miles, Solebury Trout             +1 (917) 570 7340 (Mobile) 
                                        bmiles@troutgroup.com 
Susan Duffy, Solebury Trout            +1 (917) 499 8887 (Mobile) 
                                        sduffy@troutgroup.com 
 
Investor Relations 
Xuan Yang, Solebury Trout              +1 (415) 971 9412 (Mobile) 
                                        xyang@troutgroup.com 
David Dible,                           +44 7967 566 919 (Mobile) 
 Citigate Dewe Rogerson                 david.dible@citigatedewerogerson.com 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts            +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRUWOKRWKANURR

(END) Dow Jones Newswires

June 29, 2018 02:01 ET (06:01 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024